Dr. Deepna D. Jaiswal, D.O.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 129
Licensed in Texas since 2017, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license R1782 (first issued 2017; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medical City Plano Plano, TX
- Texoma Medical Center Denison, TX
- Medical Center of Mckinney Mckinney, TX
Medical groups
- Oncology-Hematology Consultants PA (75 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 129
- Services billed
- 52,934
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg | 1,112 | 13 |
| Injection, palonosetron hcl, 25 mcg | 400 | 11 |
| Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 330 | 26 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 147 | 38 |
| Blood test, comprehensive group of blood chemicals | 142 | 42 |
| Established patient office or other outpatient visit, 30-39 minutes | 136 | 74 |
| Established patient office or other outpatient visit, 40-54 minutes | 101 | 39 |
| Injection of additional new drug or substance into vein | 97 | 15 |
| Administration of chemotherapy into vein, 1 hour or less | 94 | 22 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 71 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Plano, TX | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 29 companies reported 61 payments worth $1,321 in total to this clinician.
| Daiichi Sankyo Inc. | $295 |
|---|---|
| Pfizer Inc. | $111 |
| Merck Sharp & Dohme LLC | $77.52 |
| AstraZeneca Pharmaceuticals LP | $68.49 |
| Genzyme Corporation | $65.02 |
| GlaxoSmithKline, LLC. | $48.57 |
| Bayer HealthCare Pharmaceuticals Inc. | $46.66 |
| Janssen Biotech, Inc. | $45.87 |
| Food and Beverage | $1,252 |
|---|---|
| Education | $68.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Aug 21, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.